Quest Diagnostics (DGX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $3.00
- Estimate
- $2.87
- Surprise
- +4.4%
- Score at report (before → after)
- 5.6 → 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Quest Diagnostics (DGX) beat the $2.87 estimate with adjusted EPS of $3.00 — a clear 4.4% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Hold at 5.6/10 after the report.
Coverage in the report window
- Quest Diagnostics Discloses Unauthorized Access To Its Testing Management Platform Quanum LSM System; Company Promptly I — benzinga, 2026-10-22
Where TrendMatrix's rating stands now
TrendMatrix currently rates DGX Hold at 5.6/10.
4 of the last 4 quarters beat the estimate; this quarter's +4.4% surprise compares with a +5.8% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (2.2% away)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $243.28
- Stop
- $230.16
The stock trades at 25.8× trailing but 20.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-23 — shown for context, not personalized investment advice.
DGX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $26.85B
- P/E (fwd)
- 20.2
- P/E (ttm)
- 25.8
- 52-week range
- $171.18–$248.84
- Off 52-week high
- 2.2%
- RSI (14)
- 66
- Volume vs avg
- 1.56×
- Score today
- 5.6/10